Syndax Pharmaceuticals, Inc. (SNDX) Income Statement
SNDX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSNDX revenue and net income
Where SNDX's revenue goes
2025Each bar shows an amount and its share of revenue. SNDX kept −165.6% of revenue as net income.
SNDX profit margins
SNDX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +627.8% | +10.8% | +157.7% | +75.4% |
| Gross profit | +623.6% | — | +155.6% | +74.6% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SNDX quarterly EPS vs estimates
Syndax Pharmaceuticals beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 2, 2026 (estimate $-0.51).
SNDX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | $126.6M | $139.7M | $1.5M | $1.5M | $1.5M | $2.1M | $1.2M |
| Cost of revenue | $7.0M | $826,000 | $12,000 | $454,000 | $456,000 | $0 | $0 | $0 | $64.0M | $41.7M |
| Gross profit | $165.4M | $22.9M | −$12,000 | −$454,000 | $139.7M | $1.5M | $1.5M | $1.5M | $2.1M | $1.2M |
| Research & development | $258.8M | $241.6M | $163.0M | $118.5M | $88.2M | $50.4M | $43.0M | $60.1M | $48.2M | $31.7M |
| Sales, general & admin | $179.7M | $120.9M | $66.9M | $33.3M | $25.2M | $22.5M | $16.1M | $17.3M | $15.9M | $13.3M |
| Total operating expenses | $438.5M | $362.5M | $230.0M | $151.8M | $113.5M | $72.9M | $59.1M | $77.4M | $64.1M | $45.0M |
| Operating income | −$273.1M | −$339.7M | −$230.0M | −$151.8M | $26.2M | −$71.4M | −$57.5M | −$75.9M | −$62.0M | −$43.8M |
| Interest income | $22.7M | $26.1M | $18.6M | $5.9M | $403,000 | $841,000 | $1.6M | $1.9M | $1.4M | $956,000 |
| Interest expense | $33.8M | $4.9M | $208,000 | $3.1M | $1.9M | $2.4M | $1.6M | $1.9M | $1.4M | $956,000 |
| Income before taxes | −$285.4M | −$318.8M | −$209.4M | −$149.3M | $24.9M | −$73.2M | −$56.0M | −$74.0M | −$60.8M | −$44.5M |
| Income taxes | — | −$318.8M | — | −$5.6M | −$43,000 | −$89,000 | −$92,000 | $1.9M | −$76,000 | −$89,000 |
| Net income | −$285.4M | −$318.8M | −$209.4M | −$143.7M | $24.9M | −$73.1M | −$56.0M | −$74.0M | −$60.8M | −$44.5M |
| EBITDA | −$251.6M | −$313.8M | −$209.1M | −$151.7M | $26.3M | −$71.3M | −$57.4M | −$75.8M | −$61.9M | −$43.7M |
| EPS (diluted) | −$3.29 | −$3.73 | −$2.96 | −$2.45 | $0.43 | −$1.88 | −$1.85 | −$2.91 | −$2.89 | −$2.63 |
| Gross margin | 96.0% | 96.5% | — | −0.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −158.4% | −1,434.4% | — | −119.9% | 18.8% | −4,708.2% | −3,792.9% | −5,001.7% | −2,939.0% | −3,587.4% |
| Net margin | −165.6% | −1,346.1% | — | −113.6% | 17.8% | −4,816.7% | −3,688.5% | −4,875.5% | −2,884.3% | −3,645.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.8M | $64.9M | $68.5M | $45.9M | $38.0M | $20.0M | $7.7M | $12.5M | $3.5M | $0 | $536,000 | $0 |
| Cost of revenue | $3.2M | $2.6M | −$1.6M | $2.1M | $1.3M | $885,000 | $826,000 | $2,000 | $44.3M | $3,000 | $268,000 | $3,000 |
| Gross profit | $69.6M | $62.2M | $70.1M | $43.8M | $36.7M | $19.2M | $7.7M | $12.5M | $3.5M | −$3,000 | $268,000 | −$3,000 |
| Research & development | $68.0M | $58.8M | $78.6M | $56.3M | $62.2M | $61.6M | $65.5M | $71.0M | $48.7M | $56.5M | $55.1M | $39.1M |
| Sales, general & admin | $41.5M | $37.6M | $49.9M | $44.9M | $43.8M | $41.0M | $37.7M | $31.1M | $29.1M | $23.0M | $44.1M | $17.3M |
| Total operating expenses | $109.6M | $96.4M | $132.6M | $101.2M | $106.0M | $102.9M | $104.0M | $102.1M | $77.7M | $79.5M | $77.9M | $56.4M |
| Operating income | −$40.0M | −$34.2M | −$62.5M | −$57.4M | −$69.4M | −$83.8M | −$96.4M | −$89.6M | −$74.2M | −$79.5M | −$77.9M | −$56.4M |
| Interest income | $3.7M | $3.6M | $4.3M | $5.3M | $6.0M | $7.2M | $7.1M | $5.4M | $6.3M | $7.3M | $5.5M | $5.3M |
| Interest expense | $12.7M | $11.8M | $52.7M | $8.3M | $7.9M | $8.1M | $4.8M | $23,000 | $45,000 | $55,000 | $63,000 | $70,000 |
| Income before taxes | −$49.4M | −$42.7M | −$68.0M | −$60.7M | −$71.8M | −$84.8M | −$94.2M | −$84.1M | −$68.1M | −$72.4M | −$72.5M | −$51.1M |
| Income taxes | — | — | — | — | — | — | — | −$2,000 | — | −$40,276 | $5.0M | −$3,000 |
| Net income | −$49.4M | −$42.7M | −$68.0M | −$60.7M | −$71.8M | −$84.8M | −$94.2M | −$84.1M | −$68.1M | −$72.4M | −$72.5M | −$51.1M |
| EBITDA | −$36.7M | −$30.8M | −$15.3M | −$52.4M | −$63.9M | −$92.8M | −$89.4M | −$84.1M | −$68.0M | −$72.3M | −$72.4M | −$51.1M |
| EPS (diluted) | −$0.55 | −$0.48 | −$0.78 | −$0.70 | −$0.83 | −$0.98 | −$1.10 | −$0.98 | −$0.80 | −$0.85 | −$1.00 | −$0.73 |
| Gross margin | 95.6% | 95.9% | 102.3% | 95.4% | 96.6% | 95.6% | 100.0% | 100.0% | 100.0% | — | 50.0% | — |
| Operating margin | −54.9% | −52.7% | −91.3% | −125.2% | −182.7% | −417.9% | −1,254.8% | −716.6% | −2,120.5% | — | −14,534.5% | — |
| Net margin | −67.8% | −65.8% | −99.3% | −132.4% | −189.3% | −423.3% | −1,226.2% | −673.0% | −1,944.7% | — | −13,521.1% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SNDX's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SNDX financial results
In fiscal year 2025 (ended December 31, 2025), Syndax Pharmaceuticals reported revenue of $172.4 million, up 627.8% from the year before. It had a net loss of $285.4 million, a net profit margin of −165.6%. Diluted earnings per share came to −$3.29. Over five years revenue grew at an average rate of 157.7% a year.
See the SNDX stock overview for the latest quote and news, or the SNDX chart for price history and technical indicators.
SNDX income statement FAQ
What is Syndax Pharmaceuticals's annual revenue?
Syndax Pharmaceuticals reported total revenue of $172.4 million for fiscal year 2025, which ended on December 31, 2025. That was up 627.8% from $23.7 million the previous year.
Is Syndax Pharmaceuticals profitable?
No. Syndax Pharmaceuticals reported a net loss of $285.4 million in fiscal 2025, a net profit margin of −165.6%; its operating margin was −158.4%.
What is Syndax Pharmaceuticals's gross margin?
Syndax Pharmaceuticals's gross margin was 96.0% in fiscal 2025: for every $100 of revenue, Syndax Pharmaceuticals kept $96 after the direct cost of its products and services.
How much does Syndax Pharmaceuticals spend on research and development?
Syndax Pharmaceuticals spent $258.8 million on research and development in fiscal 2025, 150.1% of revenue.
How fast is Syndax Pharmaceuticals growing?
Revenue grew 157.7% a year on average over the last five fiscal years, from $1.5 million to $172.4 million.
What are Syndax Pharmaceuticals's earnings per share?
Syndax Pharmaceuticals earned $-3.29 per diluted share in fiscal 2025, compared with $-3.73 a year earlier.
When will Syndax Pharmaceuticals report its next earnings?
Syndax Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes.
When does Syndax Pharmaceuticals's fiscal year end?
Syndax Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.